<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44162">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02531373</url>
  </required_header>
  <id_info>
    <org_study_id>V114-005</org_study_id>
    <nct_id>NCT02531373</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)</brief_title>
  <official_title>A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Different Formulations of V114 in Healthy Adults and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the effect of different dose levels of pneumococcal
      polysaccharide and adjuvant on the safety and immunogenicity of V114 in healthy adults and
      infants.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 15, 2015</start_date>
  <completion_date type="Anticipated">June 19, 2017</completion_date>
  <primary_completion_date type="Anticipated">June 19, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with an Adverse Event (Adult Participants)</measure>
    <time_frame>Up to 1 month after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with an Adverse Event (Infant Participants)</measure>
    <time_frame>Up to 1 month after Dose 4 (up to 14 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who Discontinued the Study Due to an Adverse Event (Infant Participants)</measure>
    <time_frame>Up to 1 month after Dose 4 (up to 14 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Solicited Injection-site Adverse Event (Infant</measure>
    <time_frame>Up to 1 month after Dose 4 (up to 14 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Solicited Systemic Adverse Event (Infant Participants)</measure>
    <time_frame>Up to 1 month after Dose 4 (up to 14 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Serotype-specific Pneumococcal Antibody (Infant Participants)</measure>
    <time_frame>One month after Dose 3 (5 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Serotype-specific Pneumococcal Antibody (Adult Participants)</measure>
    <time_frame>One month after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold-rise from Baseline of Serotype-specific Pneumococcal Antibody (Adult Participants)</measure>
    <time_frame>Baseline and 1 month after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving the Serotype-specific Threshold Value of &gt;=0.35 mcg/mL at One Month after Dose 3 (Infant participants)</measure>
    <time_frame>One month after Dose 3 (5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving the Serotype-specific Threshold Value of &gt;=0.35 mcg/mL before Dose 4 (Infant participants)</measure>
    <time_frame>Before Dose 4 (10 to 13 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving the Serotype-specific Threshold Value of &gt;=0.35 mcg/mL at One Month after Dose 4 (Infant participants)</measure>
    <time_frame>One month after Dose 4 (11 to 14 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Serotype-specific Pneumococcal Antibody before Dose 4 (Infant Participants)</measure>
    <time_frame>Before Dose 4 (10 to 13 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Serotype-specific Pneumococcal Antibody at One Month After Dose 4 (Infant Participants)</measure>
    <time_frame>One month after Dose 4 (11 to 14 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>Adult: V114 Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult: V114 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult: V114 Medium Dose with Alternative Carrier Protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult: V114 High Dose with Alternative Carrier Protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant: V114 Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 at 2, 4, 6, and 12 to 15 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant: V114 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 at 2, 4, 6, and 12 to 15 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant: V114 Medium Dose with Alternative Carrier Protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant: V114 High Dose with Alternative Carrier Protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infant: Prevnar 13™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infant participants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12 to 15 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114 Medium Dose</intervention_name>
    <description>Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose</description>
    <arm_group_label>Adult: V114 Medium Dose</arm_group_label>
    <arm_group_label>Infant: V114 Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114 High Dose</intervention_name>
    <description>Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) in each 0.5 mL dose</description>
    <arm_group_label>Adult: V114 High Dose</arm_group_label>
    <arm_group_label>Infant: V114 High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114 Medium Dose with Alternative Carrier Protein</intervention_name>
    <description>Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg), and Merck Aluminum Phosphate Adjuvant (125 mcg) with alternative carrier protein in each 0.5 mL dose</description>
    <arm_group_label>Adult: V114 Medium Dose with Alternative Carrier Protein</arm_group_label>
    <arm_group_label>Infant: V114 Medium Dose with Alternative Carrier Protein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114 High Dose with Alternative Carrier Protein</intervention_name>
    <description>Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) with alternative carrier protein in each 0.5 mL dose</description>
    <arm_group_label>Adult: V114 High Dose with Alternative Carrier Protein</arm_group_label>
    <arm_group_label>Infant: V114 High Dose with Alternative Carrier Protein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13™</intervention_name>
    <description>Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose</description>
    <arm_group_label>Infant: Prevnar 13™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult Cohort: 18 to 49 years and in good health

          -  Highly unlikely to conceive from vaccination through 6 weeks after administration of
             the study vaccine.

        Infant Cohort: approximately 2 months (42 to 90 days) and in good health.

        Exclusion Criteria:

        Adult cohort: Prior administration of any pneumococcal vaccine

          -  History of invasive pneumococcal disease

          -  Known hypersensitivity to any vaccine component

          -  Known or suspected impairment of immune function

          -  Coagulation disorder contraindicating intramuscular vaccination

          -  Received a blood transfusion or blood products within 6 months

          -  Participated in another clinical study of an investigational product within 2 months

          -  Breast feeding. Infant cohort: Prior administration of any pneumococcal vaccine

          -  Known hypersensitivity to any vaccine component

          -  Known or suspected impairment of immune function

          -  History of congenital or acquired immunodeficiency

          -  Has or mother has documented Human Immunodeficiency virus (HIV) infection

          -  Has or mother has documented hepatitis B surface antigen positive result

          -  Functional or anatomic asplenia

          -  History of failure to thrive

          -  Coagulation disorder contraindicating intramuscular vaccination

          -  History of autoimmune disease or autoimmune disorder

          -  Known neurologic or cognitive behavioral disorder

          -  Received systemic corticosteroids within 14 days

          -  Received other licensed non-live vaccine within 14 days

          -  Received other licensed live virus vaccine within 30 days

          -  Received a blood transfusion or blood products

          -  Participated in another clinical study of an investigational product

          -  History of invasive pneumococcal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>August 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
    <mesh_term>Aluminum phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
